Curanex Pharmaceuticals Inc (CURX): Nasdaq/NYSE listing notice — Curanex Pharmaceuticals receives Nasdaq bid price deficiency notice; 180-day cure period

Curanex Pharmaceuticals Inc

Received Nasdaq notice on Nov 5, 2025 for bid price below $1.00 for 30 consecutive days.
Has until May 4, 2026 (180 days) to regain compliance with Minimum Bid Price.
If not cured, may qualify for additional 180-day period if eligible and cures with reverse split if needed.
Stock continues trading under symbol CURX on Nasdaq Capital Market.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Curanex Pharmaceuticals Inc received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

November 5, 2025, Curanex Pharmaceuticals Inc, a Nevada corporation (the “Company”), received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days the closing bid price for the Company’s common stock, par value $0.0001 per share (the “Common Stock”), was below $1.00 per share, which is the minimum closing bid price (the “Minimum Bid Price”) required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Notice”). This Notice has no immediate

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Curanex Pharmaceuticals Inc filing history →

Source: SEC EDGAR

accession 0001493152-25-021028

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.